Mody, Reema

Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide

Alatorre, C., Fernández Landó, L., Yu, M., Brown, K., Montejano, L., Juneau, P., Mody, R., & Swindle, R. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementMedication Adherence and Compliance

Cited by 111

Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‐month follow‐up in a real‐world setting in the United States

Mody, R., Huang, Q., Yu, M., Zhao, R., Patel, H., Grabner, M., & Landó, L. F. (2019) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementMedication Adherence and Compliance

Cited by 93

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND

Konig, M., Riddle, M. C., Colhoun, H. M., Branch, K. R., Atisso, C. M., Lakshmanan, M. C., Mody, R., Raha, S., & Gerstein, H. C. (2021) · Cardiovascular Diabetology

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 73

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD ‐11

Bonora, E., Frias, J. P., Tinahones, F. J., Van, J., Malik, R. E., Yu, Z., Mody, R., Bethel, A., Kwan, A. Y. M., & Cox, D. A. (2021) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 67

Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison

Vadher, K., Patel, H., Mody, R., Levine, J. A., Hoog, M., Cheng, A. Y., Pantalone, K. M., & Sapin, H. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 56

Long‐term cost‐effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States

Valentine, W. J., Hoog, M., Mody, R., Belger, M., & Pollock, R. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementHealth Systems, Economic Evaluations, Quality of Life

Cited by 28

Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice

Mody, R., Manjelievskaia, J., Marchlewicz, E. H., Malik, R. E., Zimmerman, N. M., Irwin, D. E., & Yu, M. (2022) · Clinical Therapeutics

Medication Adherence and ComplianceDiabetes Treatment and Management

Cited by 22

Characteristics associated with the choice of first injectable therapy among US patients with type 2 diabetes.

Yu, M., Mody, R., Landó, L. F., Shui, A., Kallenbach, L., Slipski, L., & de Oliveira, C. P. (2017) · Clinical Therapeutics

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 15